Category: psoriasis

According to a recent study, treating psoriasis with adalimumab and concomitant methotrexate has no difference in effectiveness and persistence when compared to adalimumab monotherapy.

According to a recent study, psoriasis patients with low body surface area (BSA) involvement may experience similar quality of life (QoL) and disease burden as patients with high BSA.

According to a recent study, guselkumab is effective in treating moderate-to-severe scalp psoriasis in patients with Fitzpatrick Skin Types IV through VI.

According to a recent study, patients with generalized pustular psoriasis (GPP) have a five times higher risk of all-cause mortality at one year than those without GPP.

According to a recent study, biologic treatment of psoriasis (PsO) can raise the risk of superficial fungal infections in patients, especially with interleukin (IL)-17 inhibitors.

According to a recent study, more than one-third of psoriasis patients on biologics still have increased inflammatory markers in their blood.

According to a recent study, psoriasis patients with intermediate skin phenotypes and a history of phototherapy had a higher risk of excessive sun exposure risk.

According to a recent study, female psoriasis patients have shorter drug survival for biologics compared to men.

According to a recent study, patients with generalized pustular psoriasis experience frequent flares that are typically uncontrolled by off-label therapies.

According to a recent study, an increased Body Roundness Index score, an indicator of abdominal obesity, is associated with an increased risk of psoriasis.